B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.